Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

D. russelii Venom Mediates Vasodilatation of Resistance Like Arteries via Activation of Kv and KCa Channels.

Kakumanu R, Kuruppu S, Rash LD, Isbister GK, Hodgson WC, Kemp-Harper BK.

Toxins (Basel). 2019 Apr 1;11(4). pii: E197. doi: 10.3390/toxins11040197.

2.

Vampire Venom: Vasodilatory Mechanisms of Vampire Bat (Desmodus rotundus) Blood Feeding.

Kakumanu R, Hodgson WC, Ravi R, Alagon A, Harris RJ, Brust A, Alewood PF, Kemp-Harper BK, Fry BG.

Toxins (Basel). 2019 Jan 8;11(1). pii: E26. doi: 10.3390/toxins11010026.

3.

Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.

Krishnan SM, Ling YH, Huuskes BM, Ferens DM, Saini N, Chan CT, Diep H, Kett MM, Samuel CS, Kemp-Harper BK, Robertson AAB, Cooper MA, Peter K, Latz E, Mansell AS, Sobey CG, Drummond GR, Vinh A.

Cardiovasc Res. 2019 Mar 15;115(4):776-787. doi: 10.1093/cvr/cvy252.

4.

Inflammasomes: a novel therapeutic target in pulmonary hypertension?

Scott TE, Kemp-Harper BK, Hobbs AJ.

Br J Pharmacol. 2019 Jun;176(12):1880-1896. doi: 10.1111/bph.14375. Epub 2018 Jun 27. Review.

PMID:
29847700
5.

Proteomic Identification of Interferon-Induced Proteins with Tetratricopeptide Repeats as Markers of M1 Macrophage Polarization.

Huang C, Lewis C, Borg NA, Canals M, Diep H, Drummond GR, Goode RJ, Schittenhelm RB, Vinh A, Zhu M, Kemp-Harper B, Kleifeld O, Stone MJ.

J Proteome Res. 2018 Apr 6;17(4):1485-1499. doi: 10.1021/acs.jproteome.7b00828. Epub 2018 Mar 13.

PMID:
29508616
6.

Pressor response to angiotensin II is enhanced in aged mice and associated with inflammation, vasoconstriction and oxidative stress.

Dinh QN, Drummond GR, Kemp-Harper BK, Diep H, De Silva TM, Kim HA, Vinh A, Robertson AAB, Cooper MA, Mansell A, Chrissobolis S, Sobey CG.

Aging (Albany NY). 2017 Jun 28;9(6):1595-1606. doi: 10.18632/aging.101255.

7.

Vasoactive actions of nitroxyl (HNO) are preserved in resistance arteries in diabetes.

Tare M, Kalidindi RS, Bubb KJ, Parkington HC, Boon WM, Li X, Sobey CG, Drummond GR, Ritchie RH, Kemp-Harper BK.

Naunyn Schmiedebergs Arch Pharmacol. 2017 Apr;390(4):397-408. doi: 10.1007/s00210-016-1336-1. Epub 2017 Jan 10.

PMID:
28074232
8.

The opposing roles of NO and oxidative stress in cardiovascular disease.

Ritchie RH, Drummond GR, Sobey CG, De Silva TM, Kemp-Harper BK.

Pharmacol Res. 2017 Feb;116:57-69. doi: 10.1016/j.phrs.2016.12.017. Epub 2016 Dec 15. Review.

PMID:
27988384
9.

Anakinra reduces blood pressure and renal fibrosis in one kidney/DOCA/salt-induced hypertension.

Ling YH, Krishnan SM, Chan CT, Diep H, Ferens D, Chin-Dusting J, Kemp-Harper BK, Samuel CS, Hewitson TD, Latz E, Mansell A, Sobey CG, Drummond GR.

Pharmacol Res. 2017 Feb;116:77-86. doi: 10.1016/j.phrs.2016.12.015. Epub 2016 Dec 13.

10.

Low dose dietary nitrate improves endothelial dysfunction and plaque stability in the ApoE-/- mouse fed a high fat diet.

Bakker JR, Bondonno NP, Gaspari TA, Kemp-Harper BK, McCashney AJ, Hodgson JM, Croft KD, Ward NC.

Free Radic Biol Med. 2016 Oct;99:189-198. doi: 10.1016/j.freeradbiomed.2016.08.009. Epub 2016 Aug 9.

11.

Therapeutic Potential of Nitroxyl (HNO) Donors in the Management of Acute Decompensated Heart Failure.

Kemp-Harper BK, Horowitz JD, Ritchie RH.

Drugs. 2016 Sep;76(14):1337-48. doi: 10.1007/s40265-016-0631-y. Review.

PMID:
27566478
12.

Adverse vascular remodelling is more sensitive than endothelial dysfunction to hyperglycaemia in diabetic rat mesenteric arteries.

Kahlberg N, Qin CX, Anthonisz J, Jap E, Ng HH, Jelinic M, Parry LJ, Kemp-Harper BK, Ritchie RH, Leo CH.

Pharmacol Res. 2016 Sep;111:325-335. doi: 10.1016/j.phrs.2016.06.025. Epub 2016 Jun 27.

PMID:
27363948
13.

Nitroxyl (HNO) reduces endothelial and monocyte activation and promotes M2 macrophage polarization.

Andrews KL, Sampson AK, Irvine JC, Shihata WA, Michell DL, Lumsden NG, Lim C, Huet O, Drummond GR, Kemp-Harper BK, Chin-Dusting JP.

Clin Sci (Lond). 2016 Sep 1;130(18):1629-40. doi: 10.1042/CS20160097. Epub 2016 May 26.

PMID:
27231254
14.

The Anti-fibrotic Actions of Relaxin Are Mediated Through a NO-sGC-cGMP-Dependent Pathway in Renal Myofibroblasts In Vitro and Enhanced by the NO Donor, Diethylamine NONOate.

Wang C, Kemp-Harper BK, Kocan M, Ang SY, Hewitson TD, Samuel CS.

Front Pharmacol. 2016 Mar 31;7:91. doi: 10.3389/fphar.2016.00091. eCollection 2016.

15.

Inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induced hypertension in mice.

Krishnan SM, Dowling JK, Ling YH, Diep H, Chan CT, Ferens D, Kett MM, Pinar A, Samuel CS, Vinh A, Arumugam TV, Hewitson TD, Kemp-Harper BK, Robertson AA, Cooper MA, Latz E, Mansell A, Sobey CG, Drummond GR.

Br J Pharmacol. 2016 Feb;173(4):752-65. doi: 10.1111/bph.13230. Epub 2015 Jul 31.

16.

M2 macrophage accumulation in the aortic wall during angiotensin II infusion in mice is associated with fibrosis, elastin loss, and elevated blood pressure.

Moore JP, Vinh A, Tuck KL, Sakkal S, Krishnan SM, Chan CT, Lieu M, Samuel CS, Diep H, Kemp-Harper BK, Tare M, Ricardo SD, Guzik TJ, Sobey CG, Drummond GR.

Am J Physiol Heart Circ Physiol. 2015 Sep;309(5):H906-17. doi: 10.1152/ajpheart.00821.2014. Epub 2015 Jun 12.

17.

Chronic administration of the nitroxyl donor 1-nitrosocyclo hexyl acetate limits left ventricular diastolic dysfunction in a mouse model of diabetes mellitus in vivo.

Cao N, Wong YG, Rosli S, Kiriazis H, Huynh K, Qin C, Du XJ, Kemp-Harper BK, Ritchie RH.

Circ Heart Fail. 2015 May;8(3):572-81. doi: 10.1161/CIRCHEARTFAILURE.114.001699. Epub 2015 Mar 3.

PMID:
25737497
18.

Nitroxyl: a vasodilator of human vessels that is not susceptible to tolerance.

Andrews KL, Lumsden NG, Farry J, Jefferis AM, Kemp-Harper BK, Chin-Dusting JP.

Clin Sci (Lond). 2015 Jul;129(2):179-87. doi: 10.1042/CS20140759.

PMID:
25728899
19.

NOX1 deficiency in apolipoprotein E-knockout mice is associated with elevated plasma lipids and enhanced atherosclerosis.

Sobey CG, Judkins CP, Rivera J, Lewis CV, Diep H, Lee HW, Kemp-Harper BK, Broughton BR, Selemidis S, Gaspari TA, Samuel CS, Drummond GR.

Free Radic Res. 2015 Feb;49(2):186-98. doi: 10.3109/10715762.2014.992893.

PMID:
25496431
20.

Hydrogen sulfide treatment reduces blood pressure and oxidative stress in angiotensin II-induced hypertensive mice.

Al-Magableh MR, Kemp-Harper BK, Hart JL.

Hypertens Res. 2015 Jan;38(1):13-20. doi: 10.1038/hr.2014.125. Epub 2014 Aug 7.

PMID:
25099489
21.
22.

Hydrogen sulfide protects endothelial nitric oxide function under conditions of acute oxidative stress in vitro.

Al-Magableh MR, Kemp-Harper BK, Ng HH, Miller AA, Hart JL.

Naunyn Schmiedebergs Arch Pharmacol. 2014 Jan;387(1):67-74. doi: 10.1007/s00210-013-0920-x. Epub 2013 Sep 26.

PMID:
24068103
23.

The nitric oxide redox sibling nitroxyl partially circumvents impairment of platelet nitric oxide responsiveness.

Dautov RF, Ngo DT, Licari G, Liu S, Sverdlov AL, Ritchie RH, Kemp-Harper BK, Horowitz JD, Chirkov YY.

Nitric Oxide. 2013 Nov 30;35:72-8. doi: 10.1016/j.niox.2013.08.006. Epub 2013 Sep 4.

PMID:
24012721
24.

A flow cytometric method for the analysis of macrophages in the vascular wall.

Moore JP, Sakkal S, Bullen ML, Kemp-Harper BK, Ricardo SD, Sobey CG, Drummond GR.

J Immunol Methods. 2013 Oct 31;396(1-2):33-43. doi: 10.1016/j.jim.2013.07.009. Epub 2013 Aug 6.

PMID:
23928493
25.

Nitroxyl donors retain their depressor effects in hypertension.

Irvine JC, Ravi RM, Kemp-Harper BK, Widdop RE.

Am J Physiol Heart Circ Physiol. 2013 Sep 15;305(6):H939-45. doi: 10.1152/ajpheart.00630.2012. Epub 2013 Jul 12.

26.

HNO/cGMP-dependent antihypertrophic actions of isopropylamine-NONOate in neonatal rat cardiomyocytes: potential therapeutic advantages of HNO over NO.

Irvine JC, Cao N, Gossain S, Alexander AE, Love JE, Qin C, Horowitz JD, Kemp-Harper BK, Ritchie RH.

Am J Physiol Heart Circ Physiol. 2013 Aug 1;305(3):H365-77. doi: 10.1152/ajpheart.00495.2012. Epub 2013 May 31.

27.

Nitroxyl (HNO) suppresses vascular Nox2 oxidase activity.

Miller AA, Maxwell KF, Chrissobolis S, Bullen ML, Ku JM, Michael De Silva T, Selemidis S, Hooker EU, Drummond GR, Sobey CG, Kemp-Harper BK.

Free Radic Biol Med. 2013 Jul;60:264-71. doi: 10.1016/j.freeradbiomed.2013.02.025. Epub 2013 Feb 28.

PMID:
23459072
28.

The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophy.

Irvine JC, Ganthavee V, Love JE, Alexander AE, Horowitz JD, Stasch JP, Kemp-Harper BK, Ritchie RH.

PLoS One. 2012;7(11):e44481. doi: 10.1371/journal.pone.0044481. Epub 2012 Nov 7.

29.

Nitroxyl (HNO) stimulates soluble guanylyl cyclase to suppress cardiomyocyte hypertrophy and superoxide generation.

Lin EQ, Irvine JC, Cao AH, Alexander AE, Love JE, Patel R, McMullen JR, Kaye DM, Kemp-Harper BK, Ritchie RH.

PLoS One. 2012;7(4):e34892. doi: 10.1371/journal.pone.0034892. Epub 2012 Apr 10.

30.

Vasorelaxant and antiaggregatory actions of the nitroxyl donor isopropylamine NONOate are maintained in hypercholesterolemia.

Bullen ML, Miller AA, Dharmarajah J, Drummond GR, Sobey CG, Kemp-Harper BK.

Am J Physiol Heart Circ Physiol. 2011 Oct;301(4):H1405-14. doi: 10.1152/ajpheart.00489.2011. Epub 2011 Jul 29.

31.

Nitroxyl (HNO): a novel redox signaling molecule.

Kemp-Harper BK.

Antioxid Redox Signal. 2011 May 1;14(9):1609-13. doi: 10.1089/ars.2011.3937. Epub 2011 Mar 8.

PMID:
21299468
32.

Oxidative stress and endothelial dysfunction in cerebrovascular disease.

Chrissobolis S, Miller AA, Drummond GR, Kemp-Harper BK, Sobey CG.

Front Biosci (Landmark Ed). 2011 Jan 1;16:1733-45. Review.

PMID:
21196259
33.

Chronic administration of the HNO donor Angeli's salt does not lead to tolerance, cross-tolerance, or endothelial dysfunction: comparison with GTN and DEA/NO.

Irvine JC, Kemp-Harper BK, Widdop RE.

Antioxid Redox Signal. 2011 May 1;14(9):1615-24. doi: 10.1089/ars.2010.3269. Epub 2011 Mar 3.

PMID:
20849324
34.

Nitroxyl (HNO) as a vasoprotective signaling molecule.

Bullen ML, Miller AA, Andrews KL, Irvine JC, Ritchie RH, Sobey CG, Kemp-Harper BK.

Antioxid Redox Signal. 2011 May 1;14(9):1675-86. doi: 10.1089/ars.2010.3327. Epub 2010 Nov 2. Review.

PMID:
20673125
35.

A novel role for HNO in local and spreading vasodilatation in rat mesenteric resistance arteries.

Yuill KH, Yarova P, Kemp-Harper BK, Garland CJ, Dora KA.

Antioxid Redox Signal. 2011 May 1;14(9):1625-35. doi: 10.1089/ars.2010.3279. Epub 2010 Oct 7.

36.

Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO* and beyond.

Ritchie RH, Irvine JC, Rosenkranz AC, Patel R, Wendt IR, Horowitz JD, Kemp-Harper BK.

Pharmacol Ther. 2009 Dec;124(3):279-300. doi: 10.1016/j.pharmthera.2009.08.001. Epub 2009 Aug 29. Review.

PMID:
19723539
37.

A role for nitroxyl (HNO) as an endothelium-derived relaxing and hyperpolarizing factor in resistance arteries.

Andrews KL, Irvine JC, Tare M, Apostolopoulos J, Favaloro JL, Triggle CR, Kemp-Harper BK.

Br J Pharmacol. 2009 Jun;157(4):540-50. doi: 10.1111/j.1476-5381.2009.00150.x. Epub 2009 Mar 26.

38.

Redox variants of NO (NO{middle dot} and HNO) elicit vasorelaxation of resistance arteries via distinct mechanisms.

Favaloro JL, Kemp-Harper BK.

Am J Physiol Heart Circ Physiol. 2009 May;296(5):H1274-80. doi: 10.1152/ajpheart.00008.2009. Epub 2009 Feb 27.

39.

cGMP in the vasculature.

Kemp-Harper B, Schmidt HH.

Handb Exp Pharmacol. 2009;(191):447-67. doi: 10.1007/978-3-540-68964-5_19. Review.

PMID:
19089340
40.

Nitroxyl (HNO): the Cinderella of the nitric oxide story.

Irvine JC, Ritchie RH, Favaloro JL, Andrews KL, Widdop RE, Kemp-Harper BK.

Trends Pharmacol Sci. 2008 Dec;29(12):601-8. doi: 10.1016/j.tips.2008.08.005. Epub 2008 Oct 1. Review.

PMID:
18835046
41.

Meeting report: cGMP matters.

Kemp-Harper B, Feil R.

Sci Signal. 2008 Mar 4;1(9):pe12. doi: 10.1126/stke.19pe12.

PMID:
18319447
42.

Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signaling.

Kirsch M, Kemp-Harper B, Weissmann N, Grimminger F, Schmidt HH.

FASEB J. 2008 Jan;22(1):30-40. Epub 2007 Aug 6.

PMID:
17679609
43.

Nitric oxide suppresses NADPH oxidase-dependent superoxide production by S-nitrosylation in human endothelial cells.

Selemidis S, Dusting GJ, Peshavariya H, Kemp-Harper BK, Drummond GR.

Cardiovasc Res. 2007 Jul 15;75(2):349-58. Epub 2007 Apr 21.

PMID:
17568572
44.

Endothelial dysfunction and arterial pressure regulation during early diabetes in mice: roles for nitric oxide and endothelium-derived hyperpolarizing factor.

Fitzgerald SM, Kemp-Harper BK, Parkington HC, Head GA, Evans RG.

Am J Physiol Regul Integr Comp Physiol. 2007 Aug;293(2):R707-13. Epub 2007 May 23.

45.

Definitive role for natriuretic peptide receptor-C in mediating the vasorelaxant activity of C-type natriuretic peptide and endothelium-derived hyperpolarising factor.

Villar IC, Panayiotou CM, Sheraz A, Madhani M, Scotland RS, Nobles M, Kemp-Harper B, Ahluwalia A, Hobbs AJ.

Cardiovasc Res. 2007 Jun 1;74(3):515-25. Epub 2007 Mar 3.

46.

Nitroxyl anion donor, Angeli's salt, does not develop tolerance in rat isolated aortae.

Irvine JC, Favaloro JL, Widdop RE, Kemp-Harper BK.

Hypertension. 2007 Apr;49(4):885-92. Epub 2007 Feb 19.

PMID:
17309955
47.

The nitroxyl anion (HNO) is a potent dilator of rat coronary vasculature.

Favaloro JL, Kemp-Harper BK.

Cardiovasc Res. 2007 Feb 1;73(3):587-96. Epub 2006 Nov 18.

PMID:
17189622
48.

Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels.

Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H S AK, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Müller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Müller-Esterl W, Schmidt HH.

J Clin Invest. 2006 Sep;116(9):2552-61.

49.
50.

Role of endothelium-derived hyperpolarizing factor in endothelial dysfunction during diabetes.

Fitzgerald SM, Kemp-Harper BK, Tare M, Parkington HC.

Clin Exp Pharmacol Physiol. 2005 May-Jun;32(5-6):482-7. Review.

PMID:
15854163

Supplemental Content

Loading ...
Support Center